Although influenza is, in most cases, a transient and non-serious disease, certain populations, such as the elderly or people with weakened immunity, have a greater risk of becoming infected and the disease becomes more complicated, as well as greater possibilities. of responding poorly to vaccination. The disease itself is very variable and, as a result, vaccines must be combined with specific virus strains that circulate each flu season. If therapies based on broadly neutralizing antibodies (bnAbs) have so far been unsuccessful, it is partly due to a similar lack of coverage between viral strains of influenza A and B and the need for multiple high-dose injections to maintain protection. Now, a team of researchers has found in the flames a specific type of antibodies capable of acting against several strains of influenza virus. Although the procedure has only been tested in mice, its results, published in Science, are very promising. Although vaccines are currently the most widely used tool in the management and prevention of epidemics worldwide, their effectiveness between seasons and populations continues being limited. The new finding shows promise as a preventive measure that could be immediately effective at the beginning of an epidemic.
— Including avian influenza —
Researchers led by Nick Laursen, of the Scripps Research Institute in La Jolla, California (USA), have generated a new anti-flu antibody that demonstrates lasting and universal protection against a wide variety of influenza A and B viruses. , including strains of avian transmission such as H1N1. According to the results, the rapid onset of comprehensive protection against influenza that may be able to provide protection for a whole season, particularly in elderly or immunocompromised. Scientists aim to achieve lasting protection against the virus of the Influenza-based single domain antibodies (sdAb) broadly isolated flame isolates immunized with influenza vaccines. Of these sdAbs, the authors generated a highly potent multi-domain antibody (MDAb), antibodies that can be targeted to multiple epitopes of antigens, called MD3606. In mice treated intranasally using an adenovirus vector, the antibodies provided almost universal protection against influenza A and B viruses In addition, it was shown that old and immunodeficient animals were protected against lethal doses of H1N1 avian influenza. If these preclinical findings are translated into humans, we could be facing a powerful tool to fight the flu in vulnerable populations that are not currently covered by traditional vaccination, the researchers conclude.
Source: N + 1
Follow us on twitter…